AbbVie Dividenden en inkoop

Dividend criteriumcontroles 4/6

AbbVie is een dividendbetalend bedrijf met een huidig rendement van 3.82%. Volgende betalingsdatum is op 14th February, 2025 met een ex-dividenddatum van 15th January, 2025.

Belangrijke informatie

3.8%

Dividendrendement

0.4%

Terugkoop Rendement

Totaal aandeelhoudersrendement	4.2%
Toekomstig dividendrendement	4.0%
Dividendgroei	1.3%
Volgende betaaldatum dividend	14 Feb 25
Ex-dividenddatum	15 Jan 25
Dividend per aandeel	US$6.560
Uitbetalingsratio	216%

Recente updates van dividend en inkoop

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Nov 19

Recent updates

Komende dividendbetaling

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Het dividend per aandeel van ABBV is de afgelopen 10 jaar stabiel gebleven.

Groeiend dividend: De dividendbetalingen van ABBV zijn de afgelopen 10 jaar gestegen.

Dividendrendement versus markt

AbbVie Dividendrendement versus markt

Hoe verhoudt ABBV dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (ABBV)	3.8%
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.3%
Gemiddelde industrie (Biotechs)	2.3%
Analist prognose (ABBV) (tot 3 jaar)	4.0%

Opmerkelijk dividend: Het dividend van ABBV ( 3.82% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de US markt ( 1.37% ).

Hoog dividend: Het dividend ABBV ( 3.82% ) is laag vergeleken met de top 25% van dividendbetalers in de US markt ( 4.26% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Gezien de hoge payout ratio ( 215.8% ) worden de dividendbetalingen van ABBV niet goed gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn redelijke cash payout ratio ( 74.2% ) worden de dividendbetalingen van ABBV gedekt door kasstromen.

AbbVie Dividenden en inkoop

Dividend criteriumcontroles 4/6

Belangrijke informatie

Recente updates van dividend en inkoop

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Upcoming dividend of US$1.55 per share

Upcoming dividend of US$1.55 per share

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

Recent updates

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

Investor sentiment deteriorates as stock falls 15%

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Stock: Keep Calm And Buy The Dip

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie: 3 Positives From The Earnings Report

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

AbbVie: Strong Dividends But Humira Disappoints

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Why AbbVie Remains One Of My Favorite Dividend Growers

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold US$12m worth of stock

Consensus EPS estimates fall by 10%

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie: Growth Is Still A Better Choice

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Executive Chairman notifies of intention to sell stock

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie: A Hold Again (Rating Downgrade)

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million.

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie: 5 Reasons That Make A Buy Case

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Komende dividendbetaling

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend